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extent of generic drug utilisation for the two main drug
schemes, the General Medical Services (GMS) scheme and
the Drugs Payment (DP) scheme, was measured. Under
the GMS scheme, all prescribed drugs are fully reim-
bursement by the state. Under the DP scheme the pa-
tient pays up to €70/month for prescribed drugs and the
state pays the remainder. Potential savings from generic
substitution for both schemes were investigated.
METHODS: The cost and quantity of drugs dispensed in
2001 were analysed using a national primary care pre-
scribing database, which contains information on the
brand name, strength, form and cost of prescribed drugs.
Drugs are categorised into 4 classes on the database:
generic, branded generic, proprietary drug with a generic
equivalent, proprietary drug with no generic equivalent.
The analysis was performed using JMP and SAS (SAS
Institute Inc.). RESULTS: On the GMS scheme 22% of
prescription items were dispensed generically, whereas on
the DP scheme 12% were dispensed generically. On both
the GMS and DP schemes 18% of prescription items were
dispensed as a proprietary preparation when a generic
equivalent was available. Substitution of the cheapest
generic equivalent preparation would result in estimated
annual savings of €14.54 million (3.4% of total expen-
diture) on the GMS scheme and €4.88 million (2.7% of
total expenditure) on the DP scheme. CONCLUSIONS:
The results highlight the potential cost savings, which
could be made by generic substitution, facilitating the
most efﬁcient use of the limited drugs budget.
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OBJECTIVES: The objective of this study is to describe
the current state of Philippine drug prices across various
data sources. METHODS: Retail drug price data was
gathered for a list of the 124 pharmacologically active
ingredients most commonly reimbursed by PHIC. This
list was generated from a systematic sample of 410 claims
from a total 305,482 processed claims ﬁled at the
National Capital Region ofﬁce during the calendar year
2000. This sample also served as a source of national
drug price data. Other sources of price data included a
survey of international drug prices, and a joint Depart-
ment of Health-Management Sciences for Health drug
price survey from 64 points of sale throughout the
country. RESULTS: Data gathered from local sources 
displayed a large degree of variation. From the PHIC
processed claims sample, the average relative price dif-
ference between identical drug preparations was 382.7%
(SD ± 1080.3). Similarly, price data from the joint DOH-
MSH survey displayed an average relative price difference
of 247.4% (SD ± 538.4). Comparison of local to inter-
national price data showed that Philippine prices for
certain drug products may be 10–15 times higher than
those if purchased outside of the country. CONCLU-
SIONS: The results of this study substantiate the common
belief that there is extreme variation and inﬂation of drug
prices in the Philippines. Other related studies have also
shown that these considerable discrepancies cannot be
attributed wholly to the more common reasons for 
price variance such as transportation, purchasing power,
market ﬂuctuations, etc. This study’s ﬁndings also give
PHIC further license to develop an index of drug refer-
ence prices that will serve as a basis for drug reimburse-
ment in the hope of encouraging the more rational and
fair pricing of drugs.
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OBJECTIVES: To determine ﬁnancial and professional
beneﬁts to examinees for Board of Pharmceutical Spe-
cialties (BPS) certiﬁcation. METHODS: An anonymous
web-based survey was developed and pre-tested. The
survey was sent to all 84 US colleges of pharmacy. Demo-
graphics captured included college size, mean yearly
research dollars, faculty size, and enrollment. Information
regarding numbers of BPS-certiﬁed faculty, the extent to
which BPS certiﬁcation was considered in recruitment,
and compensation/incentives provided to faculty for cer-
tiﬁcation was obtained. RESULTS: Thirty-ﬁve surveys
were returned. Deans completed surveys (54%) and divi-
sion/ department chairs (43%). Mean number of full-time
faculty members/institution was 24 (range 9–60). Mean
number of full-time board certiﬁed faculty members was
7 (20%), with a range of 0–25. No institution required
board certiﬁcation for new faculty members; 8 (23%)
anticipated such a requirement for currently non-certiﬁed
faculty. Costs to examinees are estimated with minimum
and maximum expenses varied for test cases. The survey
revealed that expenses reimbursed varied considerably,
with 34% reimbursing no expenses, 34% reimbursing a
preparatory course and examination fee, 23% reimburs-
ing the examination fee only if the examinee is success-
ful, and 11% reimbursing travel expenses. The amount
of reimbursement was tabulated. While 66% of respon-
dents stated they encouraged faculty to seek board certi-
ﬁcation, fewer had faculty incentives. Only 17% provided
salary increases and 6% granted promotion to recognize
faculty members. Most institutions considered board cer-
tiﬁcation in promotion and tenure (66%) and provided
public recognition of successful examinees (51%). Poten-
tial values were attached to the promotion and tenure and
public recognition variables based on literature values.
CONCLUSIONS: BPS certiﬁcation is not required at this
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time for any US college of pharmacy. Therefore, faculty
members should consider the costs and beneﬁts associ-
ated with pursuing such certiﬁcation. This information
may assist faculty members in resource use and decision-
making with regard to BPS certiﬁcation.
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OBJECTIVE: To describe the mechanisms and out-
comes of utilization review conducted by Philippine
Health Insurance Corporation on its health providers.
METHODS: Utilization review conducted among PHIC-
accredited health providers consisted of three compo-
nents. First part involved retrospective review of claims
database wherein the initial focus was on hospital out-
liers (i.e. small percentage of hospitals that have utiliza-
tion rates signiﬁcantly higher than their counterparts) and
identiﬁcation of utilization patterns of care and medical
services rendered. Second portion was an external review
process wherein a group of practicing physicians func-
tioned as peer review committee evaluating whether the
care provided was medically appropriate and necessary.
Third part included assessment of the rationality of drug
use in selected regions of the Philippines. RESULTS:
Based on bed occupancy rate and number of claims ﬁled,
126 PHIC-accredited facilities nationwide were identiﬁed
as outliers. Majority of the hospitals identiﬁed with
extreme utilization rates were privately owned and were
categorized as primary hospitals. Forty-eight percent
(61/126) of the hospitals identiﬁed as outliers had
extremely disproportionate reimbursements for acute
bronchitis. Among the varied clinical cases deliberated on
by the peer review committee, management in 33% was
found to be inappropriate and unnecessary. Based on
review of prescriptions, the average number of prescrip-
tions per patient encounter in selected hospitals was 3
drugs (SD ± 3). Ninety percent of these prescriptions were
written in generics. 31% of these prescriptions were for
antibiotics. One drug prescription based on existing data
costs about P321.00 (Equivalent to $ 6 per prescription).
CONCLUSION: Unnecessary, inappropriate, or exces-
sive use of medical services was identiﬁed through the 
different mechanisms of utilization review. The data gath-
ered paved the way to a feedback process for health
providers that can possibly translate into reduced inap-
propriate variations in the use of medical health care ser-
vices and then perhaps cost-savings.
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There is increasing evidence that tighter control of glucose
levels in critically ill patients improves patient outcomes.
OBJECTIVES: To determine if education and implemen-
tation of a continuous insulin infusion protocol during
2002 improved glucose control in the intensive care
setting. METHODS: A retrospective chart review was
conducted on ICU patients during a four-month period in
one of three consecutive years. Patients were included if
they were in the ICU for a minimum of three days, were
ventilated, received care from an intensivist, and had a
medical DRG at discharge. Additional information was
gathered from electronic charge data. Alpha for all analy-
ses was set at 0.05. RESULTS: The following number of
charts was reviewed for each time period: 22 in 2001, 51
in 2002, and 31 in 2003. There were no signiﬁcant dif-
ferences in patient age, gender, marital status, race, dia-
betes as a secondary diagnosis, or hospital or ICU length
of stay. Regression analysis demonstrated that median
glucose values per patient day were highest in 2001
(164.1mg/dL), compared to 2002 (136.1mg/dL) and
2003 (127.7mg/dL). The number of documented glucose
values was lowest in 2001 [2.4 per pt day (sd 2.5)], and
highest in 2002 [5.8 per pt day (sd 5.4)], compared to
2003 patients [4.3 per pt day (sd 5.2)]. CONCLUSION:
Efforts to manage glucose in the critically ill appear effec-
tive as evidenced by a higher number of documented
values/day and a decrease in median glucose values per
patient day.
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OBJECTIVES: To determine what factors can help to
predict if patients undergoing 13 different clean or clean-
contaminated procedures will get the recommended
antimicrobial prophylaxis and to investigate the associa-
tion of compliance to published surgical site infection
guidelines and other factors with hospital length of stay
(LOS). METHODS: Data included 2047 patients under-
going cardiac, gynecologic, gastrointestinal, and 
arthroplasty procedures, from 47 hospitals during a 
3-month period. Data included patient demographic, 
